Staidson (Beijing) Biopharmaceuticals Co. Ltd. Class A

Staidson (Beijing) Biopharmaceuticals Co. Ltd. Class A

SSZSE:300204
16.15
CNY
-0.34
(-2.06%)
-0.22EPS
11.07BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Staidson (Beijing) Biopharmaceuticals Co. Ltd. Class A carries a market capitalization of 11.07B, placing it among publicly traded companies globally. Its enterprise value stands at 9.99B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap11.07B
Enterprise Value9.99B

Share Statistics

As of September 30, 2026, Staidson (Beijing) Biopharmaceuticals Co. Ltd. Class A has 541.34M shares outstanding.

Shares Outstanding541.34M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 52.46, and the price-to-book ratio stands at 5.50.

PS Ratio52.46
PB Ratio5.50
P/TBV Ratio6.43

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 53.47 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 9.99B versus a market cap of 11.07B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales53.47

Financial Position

As of September 30, 2026, Staidson (Beijing) Biopharmaceuticals Co. Ltd. Class A maintains a current ratio of 17.73, meaning it holds 17.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.04, indicating conservative leverage, while an interest coverage ratio of -7.18 demonstrates limited ability to service its debt obligations.

Current Ratio17.73
Quick Ratio14.46
Debt / Equity0.04
Debt / EBITDA-0.01
Interest Coverage-7.18

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Staidson (Beijing) Biopharmaceuticals Co. Ltd. Class A posted a negative return on equity (ROE) of -6.51, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -5.52, reflecting losses generated across the asset base. The company generates approximately 380,606.79 in revenue per employee across its workforce of 491.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.60 indicates how many times Staidson (Beijing) Biopharmaceuticals Co. Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-6.51
Return on Assets (ROA)-5.52
Revenue Per Employee380,606.79
Employee Count491.00
Inventory Turnover2.60

Taxes

CNY

Over the twelve months ended September 30, 2026, Staidson (Beijing) Biopharmaceuticals Co. Ltd. Class A recorded an income tax benefit of -296,702.33 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -106.04M and -99.54M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-296,702.33

Stock Price Statistics

CNY

As of the close on November 17, 2026, Staidson (Beijing) Biopharmaceuticals Co. Ltd. Class A's stock has declined approximately 55.52% over the past 52 weeks. The 50-day moving average sits at 19.00, while the 200-day moving average is 23.82.

52-Week Price Change-55.52%
50-Day Moving Average19.00
200-Day Moving Average23.82

Income Statement

CNY

Over the twelve months ended September 30, 2026, Staidson (Beijing) Biopharmaceuticals Co. Ltd. Class A generated 186.88M in revenue and converted that into -99.54M in net income, yielding earnings per share of -0.22. EBITDA reached -104.30M, while operating income came in at -88.79M.

Revenue186.88M
Gross Profit135.63M
Operating Income-88.79M
Pretax Income-106.04M
Net Income-99.54M
EBITDA-104.30M
EBIT-104.30M
Earnings Per Share (EPS)-0.22

Balance Sheet

CNY

As of September 30, 2026, Staidson (Beijing) Biopharmaceuticals Co. Ltd. Class A holds 1.06B in cash and equivalents against 760,796.87 in total debt, resulting in a net debt position of -555.82M. Total book value stands at 2.01B, with working capital of 1.22B providing operational flexibility.

Cash & Cash Equivalents1.06B
Total Debt760,796.87
Net Debt-555.82M
Equity (Book Value)2.01B
Book Value Per Share3.71
Working Capital1.22B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-113.06M

Margins

Over the twelve months ended September 30, 2026, Staidson (Beijing) Biopharmaceuticals Co. Ltd. Class A posted a gross margin of 72.58, reflecting its pricing power and cost economics. The operating margin of -47.51 and net profit margin of -53.27 provide insight into operational efficiency.

Gross Margin72.58
Operating Margin-47.51
Pretax Margin-56.74
Profit Margin-53.27
EBITDA Margin-55.81

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Staidson (Beijing) Biopharmaceuticals Co. Ltd. Class A paid dividends of 0.01 per share. The dividend payout ratio of -2.21 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -10.70, meaning Staidson (Beijing) Biopharmaceuticals Co. Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Dividend Per Share0.01
Payout Ratio-2.21
Shareholder Yield-10.70

Stock Splits

Staidson (Beijing) Biopharmaceuticals Co. Ltd. Class A's most recent stock split took place on May 5, 2016 with a 493:690 split ratio.

Last Split Date5/5/2016
Split Ratio493:690

Scores

As of September 30, 2026, Staidson (Beijing) Biopharmaceuticals Co. Ltd. Class A has an Altman Z-Score of 18.30, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score18.30